Regulatory Story
Go to market news section View chart   Print
Company Oilex Limited
TIDM OEX
Headline

Appendix 3B

Released 07:51 25-Feb-2013
Number 5611Y07

RNS Number : 5611Y
Oilex Limited
25 February 2013
 



 

 

 

 

 

 

25 February 2013

 

 

 

 

Dear Sirs

 

Appendix 3B

 

We enclose an Appendix 3B detailing the issue of the following unlisted options on 22 February 2013:

 

1,000,000 unlisted options exercisable at $0.15 each vesting on grant date, 22 February 2013 and expiring on 30 January 2016.

 

1,000,000 unlisted options exercisable at $0.25 each vesting 30 January 2014 and expiring on 30 January 2017.

 

 

For and on behalf of Oilex Ltd

 

Robert Ierace

Chief Financial Officer / Company Secretary

 

 

cc: Directors - MC/BMc/SB/RM


Rule 2.7, 3.10.3, 3.10.4, 3.10.5

 

 

Appendix 3B

 

New issue announcement,
application for quotation of additional securities
and agreement

 

 

Information or documents not available now must be given to ASX as soon as available.  Information and documents given to ASX become ASX's property and may be made public.

 

Introduced 1/7/96.  Origin: Appendix 5.  Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005, 01/08/2012.

 

 

Name of entity

   OILEX LTD

 

ABN

    50 078 652 632 

 

We (the entity) give ASX the following information.

 

 

Part 1 ‑ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

 

1.  

+Class of +securities issued or to be issued

 

Unlisted options




2.  

Number  of +securities issued or to be issued (if known) or maximum number which may be issued

 

2 million




3.  

Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Tranche A: 1 million unlisted options exercisable at $0.15 from the 22 February 2013 and expiring on 30 January 2016;

Tranche B: 1 million unlisted options exercisable at $0.25 from the 30 January 2014 and expiring on 30 January 2017.


 




4.

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

 

If the additional securities do not rank equally, please state:

·    the date from which they do

·    the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

·    the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Not applicable.

 

 

 



5.

Issue price or consideration

 

NIL


 

 




 

6.

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

 

Sign-on employee options granted to the Chief Financial Officer who commenced 30 January 2013.




6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

 

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

No




6b

The date the security holder resolution under rule 7.1A was passed





6c

Number of +securities issued without security holder approval under rule 7.1







 

6d

Number of +securities issued with security holder approval under rule 7.1A





 



 

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

 





 



 

6f

Number of securities issued under an exception in rule 7.2





 



 

6g

If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3?  Include the issue date and both values.  Include the source of the VWAP calculation.





 



 

6h

If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements





 



 

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

45,212,311




 

7.

Dates of entering +securities into uncertificated holdings or despatch of certificates

 

 

 

22 February 2013


 

 




Number

+Class

8.

Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)

 

 

 

 

354,748,741

 

151,923,069

 

Ordinary Shares

 

Options exercisable at 15 cents expiring 7 September 2015

 

 



Number

+Class

 

9. 

Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

 

75,000

4,150,000

8,737,500

75,000

3,000,000

3,000,000

1,000,000

1,000,000

$0.50 Options due 01/08/2013

$0.30 Options due 01/07/2014

$0.37 Options due 10/11/2014

$0.63 Options due 01/08/2015

$0.15 Options due17/12/2015

$0.25 Options due 17/12/2016

$0.15 Options due 30/01/2016

$0.25 Options due 30/01/2017



 

 

 

10.    

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

 

 

 

 

 
Part 2 ‑ Bonus issue or pro rata issue [Item 11 to 33 - Not Applicable]

 

 

 

Part 3 ‑ Quotation of securities

You need only complete this section if you are applying for quotation of securities

 

34

Type of securities

(tick one)

(a)

Securities described in Part 1




(b)

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

 

 

 

Entities that have ticked box 34(a) [Items 35 to 42 - Not Applicable]

Additional securities forming a new class of securities

 

 

 

 

Quotation agreement

 

1. +Quotation of our additional +securities is in ASX's absolute discretion.  ASX may quote the +securities on any conditions it decides. 

 

2. We warrant the following to ASX.

 

·    The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

·      There is no reason why those +securities should not be granted +quotation.

·    An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act. 

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 

·    Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

·    We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted. 

·    If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

 

3.   We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

 

4.   We give ASX the information and documents required by this form.  If any information or document not available now, will give it to ASX before +quotation of the +securities begins.  We acknowledge that ASX is relying on the information and documents.  We warrant that they are (will be) true and complete.

 

                                                

 

 

 

Sign here                                                                                  Date: 25 February 2013

 

    

 

 

 

Print name:       Robert Ierace

 

 

 

 

 

 

 

 

Appendix 3B - Annexure 1

 

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

 

Part 1

 

Rule 7.1 - Issues exceeding 15% of capital

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue

253,324,885

Add the following:

•    Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2

 

22,004 (issued 21/09/2012)

  2,565 (issued 28/12/2012)

49,757 (issued 18/01/2013)

19,576 (issued 18/02/2013)

·      Number of fully paid ordinary securities issued in that 12 month period with shareholder approval

101,329,954 (issued 07/09/2012)

 

•     Number of partly paid ordinary  

      securities that became fully paid in that 12 month period

Nil

 

Note:

•    Include only ordinary securities here - other classes of equity securities cannot be added

•    Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

•           It may be useful to set out issues of securities on different dates as separate line items


Subtract the number of fully paid ordinary securities cancelled during that 12 month period

Nil

"A"

354,748,741



 

Step 2: Calculate 15% of "A"

"B"

0.15

[Note: this value cannot be changed]

Multiply "A" by 0.15

53,212,311

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:

•    Under an exception in rule 7.2

•    Under rule 7.1A

•    With security holder approval under rule 7.1 or rule 7.4

Note:

•    This applies to equity securities, unless specifically excluded - not just ordinary securities

•    Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed

•    It may be useful to set out issues of securities on different dates as separate line items

6,000,000 options(issued 20/12/2012)

2,000,000 options (issued 22/02/2013)

"C"

8,000,000

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15

Note: number must be same as shown in Step 2

53,212,311

Subtract "C"

Note: number must be same as shown in Step 3

8,000,000

Total ["A" x 0.15] - "C"

45,212,311

[Note: this is the remaining placement capacity under rule 7.1]


Part 2

 

 

Rule 7.1A - Additional placement capacity for eligible entities

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

"A"

Note: number must be same as shown in Step 1 of Part 1

N/A

Step 2: Calculate 10% of "A"

"D"

0.10

Note: this value cannot be changed

Multiply "A" by 0.10


Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

•    This applies to equity securities - not just ordinary securities

•    Include here - if applicable - the securities the subject of the Appendix 3B to which this form is annexed

•    Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

•    It may be useful to set out issues of securities on different dates as separate line items


"E"



 

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10

Note: number must be same as shown in Step 2


Subtract "E"

Note: number must be same as shown in Step 3


Total ["A" x 0.10] - "E"

 

Note: this is the remaining placement capacity under rule 7.1A

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSDFDIEFIV
Close


London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

 


Appendix 3B - RNS